Literature DB >> 22526045

Patients with multiple hepatocellular carcinomas within the UCSF criteria have outcomes after curative resection similar to patients within the BCLC early-stage criteria.

Wen-Chao Zhao1, Ning Yang, Nan Zhu, Hai-Bin Zhang, Yong Fu, Hua-Bang Zhou, Wen-Ke Cai, Ben-Dong Chen, Guang-Shun Yang.   

Abstract

BACKGROUND: Surgical strategies for the treatment of multiple hepatocellular carcinomas (HCC) remain controversial. This study compared the prognostic power of the University of California, San Francisco (UCSF) criteria with the Barcelona Clinic Liver Cancer (BCLC) early-stage criteria.
METHODS: Clinical and survival data of 162 multiple-HCC patients in Child-Pugh class A who underwent curative resection were retrospectively reviewed. Prognostic risk factors were analyzed using univariate and multivariate analyses.
RESULTS: UCSF criteria were shown to independently predict overall and disease-free survival. In patients within the UCSF criteria, 3-year overall and disease-free survivals were significantly better than in those exceeding the UCSF criteria (68 vs. 34 % and 54 vs. 26 %, respectively; both p < 0.001). There were no significant differences in 3-year overall and disease-free survival between patients within the UCSF criteria but exceeding the BCLC early stage and patients with BCLC early-stage disease (71 vs. 66 %, p = 0.506 and 57 vs. 50 %, p = 0.666, respectively). Tumors within the UCSF criteria were associated with a lower incidence of high-grade tumor (p = 0.009), microvascular invasion (p = 0.005), 3-month death (p = 0.046), prolonged Pringle's maneuver (p = 0.005), and surgical margin <0.5 cm (p < 0.001) than those exceeding the UCSF criteria. Tumors within the UCSF criteria but exceeding the BCLC early stage had invasiveness and surgical difficulty similar to those within the BCLC early-stage criteria.
CONCLUSIONS: Multiple HCC patients within the UCSF criteria benefit from curative resection. Expansion of curative treatment is justified.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22526045     DOI: 10.1007/s00268-012-1601-5

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  35 in total

1.  Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications.

Authors:  Nazario Portolani; Arianna Coniglio; Sara Ghidoni; Mara Giovanelli; Anna Benetti; Guido Alberto Massimo Tiberio; Stefano Maria Giulini
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

2.  Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

Authors:  F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

3.  Does surgical resection have a role in the treatment of large or multinodular hepatocellular carcinoma?

Authors:  Giovanni Ramacciato; Paolo Mercantini; Niccolò Petrucciani; Matteo Ravaioli; Alessandro Cucchetti; Massimo Del Gaudio; Matteo Cescon; Vincenzo Ziparo; Antonio Daniele Pinna
Journal:  Am Surg       Date:  2010-11       Impact factor: 0.688

4.  Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network: a pilot study.

Authors:  Alessandro Cucchetti; Fabio Piscaglia; Antonia D'Errico Grigioni; Matteo Ravaioli; Matteo Cescon; Matteo Zanello; Gian Luca Grazi; Rita Golfieri; Walter Franco Grigioni; Antonio Daniele Pinna
Journal:  J Hepatol       Date:  2010-03-24       Impact factor: 25.083

5.  Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma.

Authors:  Patrick P McHugh; Jeffrey Gilbert; Santiago Vera; Alvaro Koch; Dinesh Ranjan; Roberto Gedaly
Journal:  HPB (Oxford)       Date:  2010-02       Impact factor: 3.647

6.  Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma.

Authors:  Takeaki Ishizawa; Kiyoshi Hasegawa; Taku Aoki; Michiro Takahashi; Yosuke Inoue; Keiji Sano; Hiroshi Imamura; Yasuhiko Sugawara; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  Gastroenterology       Date:  2008-03-08       Impact factor: 22.682

7.  Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study.

Authors:  Tito Livraghi; Luigi Solbiati; M Franca Meloni; G Scott Gazelle; Elkan F Halpern; S Nahum Goldberg
Journal:  Radiology       Date:  2003-02       Impact factor: 11.105

8.  Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver.

Authors:  Marco Vivarelli; Alfredo Guglielmi; Andrea Ruzzenente; Alessandro Cucchetti; Roberto Bellusci; Claudio Cordiano; Antonino Cavallari
Journal:  Ann Surg       Date:  2004-07       Impact factor: 12.969

9.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

Review 10.  Liver transplantation for hepatocellular carcinoma.

Authors:  Vincenzo Mazzaferro; Yun Shin Chun; Ronnie T P Poon; Myron E Schwartz; Francis Y Yao; J Wallis Marsh; Sherrie Bhoori; Sung-Gyu Lee
Journal:  Ann Surg Oncol       Date:  2008-01-31       Impact factor: 5.344

View more
  2 in total

1.  Postoperative adjuvant transarterial chemoembolization for multinodular hepatocellular carcinoma within the Barcelona Clinic Liver Cancer early stage and microvascular invasion.

Authors:  Han Wang; Peng-Cheng Du; Meng-Chao Wu; Wen-Ming Cong
Journal:  Hepatobiliary Surg Nutr       Date:  2018-12       Impact factor: 7.293

2.  Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: A critical appraisal of the evidence.

Authors:  Ye Xin Koh; Hwee Leong Tan; Weng Kit Lye; Juinn Huar Kam; Adrian Kah Heng Chiow; Siong San Tan; Su Pin Choo; Alexander Yaw Fui Chung; Brian Kim Poh Goh
Journal:  World J Hepatol       Date:  2018-06-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.